Biostem Technologies (BSEM) 17th Annual LD Micro Main Event Conference summary

Product portfolio and technology

• Four main products target chronic wound care, with AmnioWrap2 as the lead product and Vendaje AC recently launched.

• Products serve post-acute, long-term, and skilled nursing segments, with applications in diabetic foot, pressure, and venous leg ulcers.

• BioRetain processing retains anti-inflammatory cytokines and growth factors, supporting superior wound healing.

• 70 patents cover placental tissue, BioRetain process, and other technologies, with both US and global protection.

• Products are shelf-stable for four years and processed under FDA-regulated, minimally manipulated standards.

Commercialization and market strategy

• Exclusive partnership with Venture Medical, leveraging 150+ representatives for national distribution.

• Sub-20% penetration in the post-acute space, with significant growth potential in both post-acute and acute hospital markets.

• Expansion plans include targeting GPO, IDN, and RPC contracts for acute care, and broadening payer coverage beyond Medicare.

• Commercialization success attributed to Venture Medical's rapid customer base conversion and expanded access.

• Current focus on Medicare reimbursement, with stable pricing and no immediate compression, but potential future CMS restructuring.

Clinical trials and data

• Two multi-center RCTs underway for diabetic foot ulcers, targeting 60 patients each, with primary outcome of wound closure at 12 weeks.

• A venous leg ulcer trial is planned, with data readout expected in Q2 2026.

• Retrospective studies show 27% greater efficiency and nearly 10% higher wound closure rates versus competitors and standard of care.

• Non-closed wounds treated with products saw a 93.6% improvement in area reduction over standard care.

• Clinical data supports expansion into commercial payer and GPO contracts.